Back to Report Store Home

Global Rheumatic Disorders Drugs Market to 2024 – Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

  • Published: Jan-2019
  • Report Code: GBIHC489MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2017–2024

Figure 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoarthritis, 2017–2024

Figure 3: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoporosis, 2017–2022

Figure 4: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Systemic Lupus Erythematosus, 2017–2024

Figure 5: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Psoriatic Arthritis, 2017–2024

Figure 6: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Humira ($bn), 2006–2024

Figure 7: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006–2024

Figure 8: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010–2024

Figure 9: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006–2024

Figure 10: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006–2024

Figure 11: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010–2024

Figure 12: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015–2024

Figure 13: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Prolia ($bn), 2010–2024

Figure 14: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Orencia ($bn), 2014–2023

Figure 15: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Actemra ($bn), 2016–2024

Figure 16: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Benlysta ($m), 2011–2024

Figure 17: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Forteo ($bn), 2006–2024

Figure 18: Rheumatic Disorders Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018

Figure 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Stage of Development, Molecule Type and Program Type, 2018

Figure 20: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Stage of Development, 2018

Figure 21: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecule Type, 2018

Figure 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Molecular Target, 2018

Figure 23: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecular Target, 2018

Figure 24: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Attrition Rate by Stage of Development (%), 2006–2018

Figure 25: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006–2018

Figure 26: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006–2018

Figure 27: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006–2018

Figure 28: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018

Figure 29: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006–2018

Figure 30: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2018

Figure 31: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006–2018

Figure 32: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018

Figure 33: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006–2018

Figure 34: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2018

Figure 35: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006–2018

Figure 36: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018

Figure 37: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006–2018

Figure 38: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2018

Figure 39: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006–2018

Figure 40: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Upadacitinib tartrate ($bn), 2019–2024

Figure 41: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Filgotinib ($bn), 2019–2024

Figure 42: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Lenabasum ($bn), 2021–2024

Figure 43: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Evenity (romosozumab) ($m), 2019–2024

Figure 44: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Avacopan ($m), 2021–2024

Figure 45: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Pegadricase ($m), 2020–2024

Figure 46: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Anifrolumab ($m), 2019–2024

Figure 47: Rheumatic Disorders Drugs Market, Global, Market Size ($bn), 2017–2024

Figure 48: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024

Figure 49: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-a ($bn), 2017–2024

Figure 50: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins and Interleukin Receptors ($bn), 2017–2024

Figure 51: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Protein Kinases ($bn), 2017–2024

Figure 52: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Targeting Cell Surface Antigens ($bn), 2017–2024

Figure 53: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Hormone Receptors ($bn), 2017–2024

Figure 54: Rheumatic Disorders Drugs Market, Global, Company Analysis Matrix, 2017–2024

Figure 55: Rheumatic Disorders Drugs Market, Global, Cluster by Growth and Market Share, 2017–2024

Figure 56: Rheumatic Disorders Drugs Market, Global, Forecast Market Share by Company (%), 2017–2024

Figure 57: Rheumatic Disorders Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024

Figure 58: Rheumatic Disorders Market, Global, Revenues by Route of Acquisition, 2017–2024

Figure 59: Rheumatic Disorders Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017–2024

Figure 60: Rheumatic Disorders Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017–2024

Figure 61: Rheumatic Disorders Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024

Figure 62: Rheumatic Disorders Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2017–2024

Figure 63: Rheumatic Disorders Drugs Market, Global, Pfizer Annual Revenue Forecast ($bn), 2017–2024

Figure 64: Rheumatic Disorders Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2017–2024

Figure 65: Rheumatic Disorders Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2017–2024

Figure 66: Rheumatic Disorders Drugs Market, Global, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2017–2024

Figure 67: Rheumatic Disorders Drugs Market, Global, Companies by Type, 2018

Figure 68: Rheumatic Disorders Drugs Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Rheumatic Disorders Specialization, 2018

Figure 69: Rheumatic Disorders Drugs Market, Global, Proportion of Total Company Revenue Attributed to Rheumatic Disorders, 2017–2024

Figure 70: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Region, Year and Value, 2006–2018

Figure 71: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Indication, 2006–2018

Figure 72: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018

Figure 73: Rheumatic Disorders Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018

Figure 74: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 1)

Figure 75: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 2)

Figure 76: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 3)

Figure 77: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 4)

Figure 78: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 5)

Figure 79: Rheumatic Disorders Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 6)

Figure 80: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018

Figure 81: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Indication, 2006–2018

Figure 82: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018

Figure 83: Rheumatic Disorders Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018

Figure 84: Rheumatic Disorders Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 1)

Figure 85: Rheumatic Disorders Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 2)

Figure 86: Rheumatic Disorders Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 3)

Figure 87: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 1

Figure 88: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 2

Figure 89: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 3

Figure 90: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 4

Figure 91: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 5

Figure 92: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 6

Figure 93: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 7

Figure 94: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 8

Figure 95: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 9

Figure 96: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 10

Figure 97: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 11

Figure 98: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 12

Figure 99: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 13

Figure 100: Rheumatic Disorders Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 14

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards